Clinical trials: Higher-risk Myelodysplastic Syndrome
AML and High Risk MDS
A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.
- Trial name
- NCT02078609
- Testing
- LGH447, LGH447 + midostaurin
- Where
- 9 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
This is a prospective phase II clinical study planned to be conducted at the Medical College of Wisconsin (MCW). After meeting the study criteria and enrollment, patients will be treated with a cladribine based salvage regimen…
- Trial name
- NCT03150004
- Testing
- Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Cladribine and Cytarabine (CLLDAC) Regimen
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Medical College of Wisconsin
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
This phase I trial tests the safety, side effects, best dose, and effectiveness of 225Ac-DOTA-Anti-CD38 daratumumab monoclonal antibody in combination with fludarabine, melphalan and total marrow and lymphoid irradiation (TMLI)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT06287944
- Testing
- Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
AML/MDS
Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
The aim of this study is to investigate how safe and effective the addition of the new medicine midostaurin to decitabine is for the treatment of unfit acute myeloid leukemia (AML) and high-risk myelodysplasia (MDS) patients.
- Trial name
- HO155 (NCT04097470)
- Testing
- Decitabine, Midostaurin
- Where
- 37 sites in Belgium, Germany and 2 more
- Volunteers
- 140 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
This research study is studying a targeted therapy combined with chemotherapy as a possible treatment for acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS).
- Trial name
- NCT03735446
- Testing
- Prexasertib, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Dana-Farber Cancer Institute
Higher-risk Myelodysplastic Syndromes
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic…
- Trial name
- NCT06196203
- Testing
- AK117, Azacitidine
- Where
- 15 sites in United States, China
- Volunteers
- 90 people
- Sponsor
- Akeso
High-risk Myelodysplastic Syndromes With Excess Blasts
High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)
Myelodysplastic syndromes (MDS) are the most frequent myeloid neoplasms in Western Countries.They mainly affect patients aged 65 years or older.
- Trial name
- MYRAGE (NCT03217903)
- Testing
- Myelogram
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Central Hospital, Nancy, France
High Risk Hematological Malignancy, Cord Blood Transplant
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality.
- Trial name
- NCT04103879
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 30 people
- Sponsor
- ExCellThera inc.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
There are no strategies developed post-stem cell transplant (SCT) for patients who receive allogenic SCT with a significant amount of blasts prior SCT.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Trial name
- NCT04361058
- Testing
- Nivolumab
- Where
- United States
- Sponsor
- SCRI Development Innovations, LLC
Leukemia, Acute Myeloid Leukemia
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest tolerable dose of nivolumab that can be give in combination with idarubicin and cytarabine in patients with MDS and AML.
- Conditions
- Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02464657
- Testing
- Nivolumab, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies.
- Conditions
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm
- Trial name
- ADAPT-HEM (NCT07523555)
- Testing
- Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Beijing Biotech
High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1
Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome
This phase II trial studies the side effects of azacitidine and pembrolizumab and to see how well they work in treating patients with myelodysplastic syndrome.
- Conditions
- High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome
- Trial name
- NCT03094637
- Testing
- Azacitidine, Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed Acute Leukemia, Refractory Acute Leukemia
A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
1.1 Primary Objectives To determine the feasibility, tolerability, and toxicities of administering the selective CDK 4/6 inhibitor PD 0332991 prior to the combination of ara-C and Mitoxantrone for adults with relapsed and…
- Conditions
- Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
- Trial name
- NCT01701375
- Testing
- PD 0332991
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who…
- Trial name
- NCT02775903
- Testing
- Azacitidine, Durvalumab
- Where
- 103 sites in United States, Austria and 10 more
- Volunteers
- 213 people
- Sponsor
- Celgene
Myelodysplastic Syndromes
A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).
- Trial name
- NCT07722988
- Testing
- Roxadustat
- Volunteers
- 201 people
- Sponsor
- Kyntra Bio
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
This phase II trial studies the effect of venetoclax together with busulfan, cladribine, and fludarabine in treating patients with high-risk acute myeloid leukemia or myelodysplastic syndrome who are undergoing stem cell…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT04708054
- Testing
- Busulfan, Cladribine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome
- Trial name
- NCT04262843
- Testing
- Cyclophosphamide, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
This phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the…
- Trial name
- NCT07153497
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00334074
- Testing
- Clofarabine and Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute